BAM
IOVA icon

Bruderman Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Bruderman Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-100
Closed -$1K – 325
2019
Q1 		$1K Hold
100
– – ﹤0.01% 603
2018
Q4 		$1K Buy
+100
New +$964 ﹤0.01% 610

Other funds holding IOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Bruderman Asset Management's IOVA Position: Q2 2019 in Review

Bruderman Asset Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2019, closing a stake of 100 shares — an estimated $1K sold.

Bruderman Asset Management first reported a position in IOVA in Q4 2018 and held it in 2 quarters. The position peaked at $1K in Q1 2019. 167 funds tracked by Wall St. Rank hold IOVA as of Q2 2019.

  • Bruderman Asset Management reported no remaining Iovance Biotherapeutics position as of Q2 2019 after selling out during the quarter.
  • Bruderman Asset Management sold 100 Iovance Biotherapeutics shares in Q2 2019, an estimated $1K.
  • Bruderman Asset Management first reported a position in Iovance Biotherapeutics in Q4 2018 and held it in 2 quarters.
  • Bruderman Asset Management's Iovance Biotherapeutics position peaked at $1K in Q1 2019.
  • 167 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2019.

Based on Bruderman Asset Management's 13F filing for Q2 2019, filed 12 Aug 2019.